Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2024 Vol. 2 > No. 1 > 100056
Next Article Previous Article
COMMENTARY   Open Access     Cite

Breaking a bottleneck for on-target toxicity: A mutant-selective PI3Kα inhibitor finally comes

  • 1.

    Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China

  • 2.

    Department of Pathology, Affiliated Tongren Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200336, China

  • 3.

    Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China

  • 4.

    Laboratory of Targeted Therapy and Precision Medicine, Department of Clinical Laboratory, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China

More Information
The Innovation Medicine  2(1),  https://doi.org/10.59717/j.xinn-med.2024.100056  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] André, F., Ciruelos, E., Rubovszky, G., et al. (2019). Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380: 1929−1940. DOI: 10.1056/NEJMoa1813904.

    View in Article CrossRef Google Scholar Scopus

    [2] Varkaris, A., Pazolli, E., Gunaydin, H., et al. (2024). Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discov. 14: 240−257. DOI: 10.1158/2159-8290.Cd-23-0944.

    View in Article CrossRef Google Scholar

    [3] Labrie, M., Brugge, J.S., Mills, G.B., et al. (2022). Therapy resistance: Opportunities created by adaptive responses to targeted therapies in cancer. Nat. Rev. Cancer 22: 323−339. DOI: 10.1038/s41568-022-00454-5.

    View in Article CrossRef Google Scholar

    [4] Varkaris, A., Fece de la Cruz, F., Martin, E.E., et al. (2024). Allosteric PI3Kα inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer Discov. 14: 227−239. DOI: 10.1158/2159-8290.Cd-23-0704.

    View in Article CrossRef Google Scholar

    [5] Fan, Y. and Xu, B. (2023). CDK4/6 inhibition: What’s happening beyond CDK4/6 inhibition may also matter. The Innovation Medicine 1: 100016. DOI: 10.59717/j.xinn-med.2023.100016.

    View in Article CrossRef Google Scholar Scopus

    • Cited by

  • Cite this article:

    Zhang Y., Duan J., Liu Y., et al., (2024). Breaking a bottleneck for on-target toxicity: A mutant-selective PI3Kα inhibitor finally comes. The Innovation Medicine 2(1): 100056. https://doi.org/10.59717/j.xinn-med.2024.100056
    Zhang Y., Duan J., Liu Y., et al., (2024). Breaking a bottleneck for on-target toxicity: A mutant-selective PI3Kα inhibitor finally comes. The Innovation Medicine 2(1): 100056. https://doi.org/10.59717/j.xinn-med.2024.100056

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(6908) PDF downloads(4002)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.